Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI)

• E. Grande ^[1] ; J. Santamaría Sandi ^[7] ; J. Capdevila ^[8] ; E. Navarro González ^[2] ; C. Zafón Llopis ^[8] ; T. Ramón y Cajal Asensio ^[3] ; J. M. Gómez Sáez ^[9] ; P. Jiménez-Fonseca ^[4] ; G. Riesco-Eizaguirre ^[5] ; J. C. Galofré ^[6]
  1. [1] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  2. [2] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  3. [3] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  4. [4] Hospital Universitario Central de Asturias

     Hospital Universitario Central de Asturias

     Oviedo, España

     
  5. [5] Hospital de Móstoles

     Hospital de Móstoles

     Móstoles, España

     
  6. [6] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
  7. [7] Hospital Universitario de Cruces, España
  8. [8] Hospital Universitario Vall d’Hebron, España
  9. [9] Hospital Universitario de Bellvitge, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 8 (August 2016), 2016, págs. 769-775
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 2 Citas
• Resumen

  • Background Of all thyroid cancers, <5 % are medullary (MTC). It is a well-characterized neuroendocrine tumor arising from calcitonin-secreting C cells, and RET gene plays a central role on its pathogeny.

    Methods The electronic search was conducted using MEDLINE (PubMed), EMBASE and Cochrane Central Register of Controlled Trials. Quality assessments of selected current articles, guidelines and reviews of MTC were performed.

    Results This consensus updates and summarizes biology, treatment and prognostic considerations of MTC.

    Conclusions Multidisciplinary teams and specialized centers are recommended for the management of MTC patients. In the metastatic setting, those patients with large volume of disease are candidates to start systemic treatment mainly if they are symptomatic and the tumor has progressed in the last 12–14 months. Wait and see strategy should be offered to patients with: disseminated disease with only high levels of calcitonin and no macroscopic structural disease, low burden and absence of progression.